Infinity Pharmaceuticals, Inc. (INFI) Financial Statements (2024 and earlier)

Company Profile

Business Address 1100 MASSACHUSETTS AVENUE
CAMBRIDGE, MA 02138
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments38,31380,72634,10842,44458,59157,609
Cash and cash equivalents38,31380,72628,59322,26048,61634,607
Short-term investments   5,51520,1849,97523,002
Restricted cash and investments   150   
Prepaid expense1,4291,1431,5281,680641563
Other current assets560399234457586214
Total current assets:40,30282,26836,02044,58159,81858,386
Noncurrent Assets
Operating lease, right-of-use asset6971,0641,4191,717
Property, plant and equipment8001,2411,7102,18628219
Restricted cash and investments158158165315  
Other noncurrent assets194545215369748
Total noncurrent assets:1,8492,5173,2994,433397967
TOTAL ASSETS:42,15184,78539,31949,01460,21559,353
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,66513,30011,0479,6987,7185,595
Accounts payable4,4052,3202,9821,6211,197459
Accrued liabilities1,26010,9808,0658,0776,5215,136
Debt      6,000
Other undisclosed current liabilities7,963     
Total current liabilities:13,62813,30011,0479,6987,71811,595
Noncurrent Liabilities
Long-term debt and lease obligation:  9171,4361,926  
Liabilities, other than long-term debt 361270245383828
Other liabilities 37270245383828
Operating lease, liability 3249171,4361,926
Other undisclosed noncurrent liabilities47,21348,72749,58029,626  
Total noncurrent liabilities:47,57449,91451,26131,5903828
Total liabilities:61,20263,21462,30841,2887,75611,623
Equity
Equity, attributable to parent(19,051)21,571(22,989)7,72652,45947,730
Common stock898964575751
Additional paid in capital836,812833,065743,269733,486731,178715,213
Accumulated other comprehensive income (loss)   (1)12(4)(15)
Accumulated deficit(855,952)(811,583)(766,321)(725,829)(678,772)(667,519)
Total equity:(19,051)21,571(22,989)7,72652,45947,730
TOTAL LIABILITIES AND EQUITY:42,15184,78539,31949,01460,21559,353

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2,5931,8581,7193,04922,1466,000
Revenue, net6,000
Gross profit:2,5931,8581,7193,04922,1466,000
Operating expenses(47,437)(46,941)(40,216)(48,713)(34,075)(42,445)
Operating loss:(44,844)(45,083)(38,497)(45,664)(11,929)(36,445)
Nonoperating income (expense)475(179)(1,995)(1,447)676(6,105)
Investment income, nonoperating    1,116  
Other nonoperating income6551450 7691,787
Interest and debt expense(180)(180)(153)(2,563)(93)(1,010)
Other undisclosed income from continuing operations before equity method investments, income taxes   1532,563931,010
Loss from continuing operations before income taxes:(44,549)(45,442)(40,492)(47,111)(11,253)(42,550)
Income tax benefit    54 720
Loss from continuing operations:(44,549)(45,442)(40,492)(47,057)(11,253)(41,830)
Loss before gain (loss) on sale of properties:(45,442)(40,492)(47,057)(11,253)(41,830)
Net loss:(44,549)(45,442)(40,492)(47,057)(11,253)(41,830)
Other undisclosed net income attributable to parent180180    
Net loss available to common stockholders, diluted:(44,369)(45,262)(40,492)(47,057)(11,253)(41,830)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(44,549)(45,442)(40,492)(47,057)(11,253)(41,830)
Comprehensive loss:(44,549)(45,442)(40,492)(47,057)(11,253)(41,830)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent180181(13)1611(12)
Comprehensive loss, net of tax, attributable to parent:(44,369)(45,261)(40,505)(47,041)(11,242)(41,842)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: